Clinical Trial

PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The primary purposes of this study are to determine the safety and tolerability of PQ203 in patients with advanced solid tumors including triple negative breast cancer (TNBC), and to determine a recommended Phase 2 dose level for future studies in TNBC.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-09-16; most recent amendment 2026-02-19.
Trial Details
NCT Number NCT07190469
Lead Sponsor ProteinQure Inc.
Conditions Triple Negative Breast Cancer (TNBC), Advanced Solid Tumors Cancer
Enrollment 80 participants
Start Date 2025-09-16
Primary Completion 2028-12 (estimated)
Study Completion 2029-02 (estimated)
Updated on ClinicalTrials.gov 2026-02-23